Showing results (131-140 of 257) with videos related to
Sort By:
Pageof 26
Hematological Oncology|August 8, 2025
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE StudyAlessandra Iurlo, Massimo Breccia, Fabio Stagno, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patientsIlaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti, et al.Leukemia & Lymphoma|October 25, 2019
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE studyNeil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP reportGiovanni Martinelli, Ilaria Iacobucci, Clelia Tiziana Storlazzi, et al.Cancers|November 13, 2021
Droplet Digital PCR for BCR-ABL1 Monitoring in Diagnostic Routine: Ready to Start?Maria Teresa Bochicchio, Jessica Petiti, Paola Berchialla, et al.Annals of Hematology|October 4, 2011
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre studyEsther Natalie Oliva, Andrea Piccin, Maria Gabriella Mazzucconi, et al.Haematologica|March 23, 2010
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseFrancesca Palandri, Fausto Castagnetti, Ilaria Iacobucci, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatmentIlaria Iacobucci, Gianantonio Rosti, Marilina Amabile, et al.Blood|February 6, 2014
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuriaAntonio M Risitano, Daniel Ricklin, Yijun Huang, et al.Pageof 26